Hamre HJ, Glockmann A, Heckenbach K, Matthes H. Use and safety of anthroposophic medicinal products: an analysis of 44,662 patients from the EvaMed Pharmacovigilance Network. Drugs - Real World Outcomes 2017;4(4):199-213.

ESCAMP evaluation stage 2: Evaluation of AMP therapy as a whole system


EvaMed was a prospective pharmacovigilance study with the patients of 38 physicians in outpatient care in Germany. Diagnoses and prescriptions were extracted from the electronic medical records of all patients. ADRs to all prescribed medicinal products were documented at follow-up visits. In the years 2001-2010, a total of 44,662 patients with 311,731 AMP prescriptions, comprising 1722 different AMPs, were included with a median follow-up of 21.7 months. Adverse reactions to AMPs were rare (0.071% of prescriptions), serious adverse reactions were very rare (0.0003%).